Methods based on the detection of RAD51 foci in tumor cells
US12007393B2 · kind B2 · utility
0Cited by
0References
7Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Dec 21, 2018 |
| Grant date | Jun 11, 2024 |
| Priority date | — |
| Expiry date | Jan 3, 2041 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/52
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides a method allowing to determine whether a subject diagnosed with cancer is sensitive or resistant to an anti-cancer treatment, based on the level of cells with RAD51 foci in a sample containing tumor cells isolated from said subject, wherein the subject has not received at 24 hours prior to the isolation of the sample, a chemotherapy selected from the group consisting of AC, FEC, ECF and navelbine/epirubicin, and wherein the sample has not been treated with a method that induces DNA damage before determining the level of cells with RAD51 foci.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.